Department of Haematology/Oncology, University Medical Centre, Freiburg, Germany.
Immunology. 2010 Apr;129(4):536-46. doi: 10.1111/j.1365-2567.2009.03209.x. Epub 2009 Dec 2.
The human chemokine receptor CRAM (chemokine receptor on activated macrophages), encoded by the gene CCRL2, is a new candidate for the atypical chemokine receptor family that includes the receptors DARC, D6 and chemocentryx chemokine receptor (CCX-CKR). CRAM is maturation-stage-dependently expressed on human B lymphocytes and its surface expression is up-regulated upon short-term CCL5 exposure. Here, we demonstrate that the homeostatic chemokine CCL19 is a specific ligand for CRAM. In radioactive labelling studies CCL19 bound to CRAM-expressing cells with an affinity similar to the described binding of its other receptor CCR7. In contrast to the known CCL19/CCR7 ligand/receptor pair, CRAM stimulation by CCL19 did not result in typical chemokine-receptor-dependent cellular activation like calcium mobilization or migration. Instead, we demonstrate that CRAM is constitutively recycling via clathrin-coated pits and able to internalize CCL19 as well as anti-CRAM antibodies. As this absence of classical chemokine receptor responses and the recycling and internalization features are characteristic for non-classical chemokine receptors, we suggest that CRAM is the newest member of this group. As CCL19 is known to be critically involved in lymphocyte and dendritic cell trafficking, CCL19-binding competition by CRAM might be involved in modulating these processes.
人源趋化因子受体 CRAM(激活巨噬细胞上的趋化因子受体),由基因 CCRL2 编码,是包括受体 DARC、D6 和 chemocentryx 趋化因子受体(CCX-CKR)在内的非典型趋化因子受体家族的新候选者。CRAM 在人类 B 淋巴细胞上的表达依赖于成熟阶段,其表面表达在短期 CCL5 暴露后上调。在这里,我们证明了稳态趋化因子 CCL19 是 CRAM 的特异性配体。在放射性标记研究中,CCL19 与表达 CRAM 的细胞结合,亲和力类似于其另一个受体 CCR7 的描述结合。与已知的 CCL19/CCR7 配体/受体对不同,CRAM 被 CCL19 刺激不会导致典型的趋化因子受体依赖性细胞激活,如钙动员或迁移。相反,我们证明 CRAM 通过网格蛋白包被小窝进行组成型再循环,并且能够内化 CCL19 以及抗 CRAM 抗体。由于这种缺乏典型趋化因子受体反应以及再循环和内化特性是典型的非典型趋化因子受体,因此我们认为 CRAM 是该组的最新成员。由于已知 CCL19 对于淋巴细胞和树突状细胞的迁移至关重要,CRAM 与 CCL19 的结合竞争可能参与调节这些过程。